Petrus R. de Jong

Petrus R. (Ruud) de Jong, MD, PhD, is currently the Head of Translational Medicine and Early Clinical Development at Endeavor Biomedicines, leading the medical and translational efforts for ENV-501. Prior to this role, Petrus served as Medical Director at ACELYRIN, INC., where responsibilities included clinical development for Lonigutamab and SLRN-517, along with strategic leadership and KOL engagement. At Zentalis Pharmaceuticals, Petrus held dual roles as Associate Director of Clinical Development and Translational Biology, focusing on the planning and execution of clinical trials for the Wee1 inhibitor azenosertib. Additional experience includes positions at Bristol-Myers Squibb, Sanford Burnham Prebys Medical Discovery Institute, and University of California at San Diego, alongside a strong academic background with multiple degrees from Utrecht University, culminating in a Ph.D. in Medicine.